Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 154-160

  Chono, Koji ^a   Katsumata, Kiyomitsu ^a   Suzuki, Hiroshi ^a   Shiraki, Kimiyasu ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Amenamevir; Combination therapy; Helicase primase inhibitor; HSV 1; HSV 2; VZV

Indexed keywords

ACICLOVIR; AMENAMEVIR; PENCICLOVIR; VALACICLOVIR; VIDARABINE;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMATITIS HERPETIFORMIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION;

ANIMALS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HERPES ZOSTER; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; OXADIAZOLES; TREATMENT OUTCOME; VERO CELLS; VIRAL PLAQUE ASSAY;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 84871941189     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.006     Document Type: Article

References (37)

1. Biron K.K., Elion G.B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob. Agents Chemother. 1980, 18:443-447.
2. Brady R.C., Bernstein D.I. Treatment of herpes simplex virus infections. Antiviral Res. 2004, 61:73-81.
3. Chono K., Katsumata K., Kontani T., Kobayashi M., Sudo K., Yokota T., Konno K., Shimizu Y., Suzuki H. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 2010, 65:1733-1741.
4. Crute J.J., Grygon C.A., Hargrave K.D., Simoneau B., Faucher A.M., Bolger G., Kibler P., Liuzzi M., Cordingley M.G. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 2002, 8:386-391.
5. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA 1977, 74:5716-5720.
6. Falkenberg M., Elias P., Lehman I.R. The herpes simplex virus type 1 helicase-primase. Analysis of helicase activity. J. Biol. Chem. 1998, 273:32154-32157.
7. Fatahzadeh M., Schwartz R.A. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007, 57:737-763. (quiz 764-736).
8. Field H.J., Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist. Updat. 2011, 14:45-51.
9. Gephart J.F., Lerner A.M. Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis. Antimicrob. Agents Chemother. 1981, 47:331-385.
10. Greco W.R., Bravo G., Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 1995, 47:331-385.
11. Greco W.R., Park H.S., Rustum Y.M. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1990, 50:5318-5327.
12. Kamiyama T., Kurokawa M., Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J. Gen. Virol. 2001, 82:2761-2765.
13. Kleymann G. Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir. Chem. Chemother. 2004, 15:135-140.
14. Kleymann G., Fischer R., Betz U.A., Hendrix M., Bender W., Schneider U., Handke G., Eckenberg P., Hewlett G., Pevzner V., Baumeister J., Weber O., Henninger K., Keldenich J., Jensen A., Kolb J., Bach U., Popp A., Maben J., Frappa I., Haebich D., Lockhoff O., Rubsamen-Waigmann H. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 2002, 8:392-398.
15. Kuramoto T., Daikoku T., Yoshida Y., Takemoto M., Oshima K., Eizuru Y., Kanda Y., Miyawaki T., Shiraki K. Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J. Pharmacol. Exp. Ther. 2010, 333:816-821.
16. Kurokawa M., Hozumi T., Tsurita M., Kadota S., Namba T., Shiraki K. Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. J. Pharmacol. Exp. Ther. 2001, 297:372-379.
17. Liptak L.M., Uprichard S.L., Knipe D.M., Liptak L.M., Uprichard S.L., Knipe D.M. Functional order of assembly of herpes simplex virus DNA replication proteins into prereplicative site structures. J. Virol. 1996, 70:1759-1767.
18. Meletiadis J., Mouton J.W., Meis J.F., Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 2003, 47:106-117.
19. Miller W.H., Miller R.L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J. Biol. Chem. 1980, 255:7204-7207.
20. Miller W.H., Miller R.L. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 1982, 31:3879-3884.
21. Miwa N., Kurosaki K., Yoshida Y., Kurokawa M., Saito S., Shiraki K. Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus. Antiviral Res. 2005, 65:49-55.
22. Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 2003, 26:29-37.
23. Muller W.E., Zahn R.K., Bittlingmaier K., Falke D. Inhibition of herpesvirus DNA synthesis by 9-beta-D-arabinofuranosyladenine in cellular and cell-free systems. Ann. N. Y. Acad. Sci. 1977, 284:34-48.
24. Muylaert I., Tang K.-W., Elias P. Replication and recombination of herpes simplex virus DNA. J. Biol. Chem. 2011, 286:15619-15624.
25. Nagafuchi S., Oda H., Mori R., Taniguchi T. Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J. Gen. Virol. 1979, 44:715-723.
26. Pellet P.E., Roizman B. The family Herpesviridae: a brief introduction. Fields Virology 2007, 2479-2499. Lippincott Williams & Wilkins, Philadelphia. fifth ed. D. Knipe, P.M. Howley, D.E. Griffin, M.A. Martin, R.A. Lamb, B. Roizman, S.E. Straus (Eds.).
27. Safrin S., Elbeik T., Phan L., Robinson D., Rush J., Elbaggari A., Mills J. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 1994, 38:1246-1250.
28. Schinazi R.F., Nahmias A.J. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Am. J. Med. 1982, 73:40-48.
29. Schwartz P.M., Novack J., Shipman C., Drach J.C. Metabolism of arabinosyladenine in herpes simplex virus-infected and uninfected cells. Correlation with inhibition of DNA synthesis and role in antiviral selectivity. Biochem. Pharmacol. 1984, 33:2431-2438.
30. Shimada Y., Suzuki M., Shirasaki F., Saito E., Sogo K., Hasegawa M., Takehara K., Phromjai J., Chuhjo T., Shiraki K. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. J. Med. Virol. 2007, 79:1731-1740.
31. Shiraki K., Ogino T., Yamanishi K., Takahashi M. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine. Biken J. 1983, 26:17-23.
32. Suzuki M., Okuda T., Shiraki K. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006, 72:157-161.
33. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 2001, 298:865-872.
34. Tyler K.L. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes 2004, 11(Suppl 2):57A-64A.
35. Tyring S., Wald A., Zadeikis N., Dhadda S., Takenouchi K., Rorig R. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J. Infect. Dis. 2012, 205:1100-1110.
36. Whitley R.J., Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin. Infect. Dis. 1995, 20:414-420.
37. Whitley R.J., Roizman B. Herpes simplex virus infections. Lancet 2001, 357:1513-1518.